HCV Core Protein Protein (AA 2-192) (beta-Gal)

Produktnummer ABIN621534

Produktdetails

Target: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Protein-Typ: Recombinant

Proteineigenschaft: AA 2-192

Spezies: Hepatitis C Virus (HCV)

Wirt: Bitte anfragen

Aufreinigungstag / Konjugat: Dieses HCV Core Protein Protein ist gelabelt mit beta-Gal.

Applikation: Western Blotting (WB), ELISA

Sequenz: mstnpkpqrk tkrntnrrpq dvkfpgvgqi vggvyllprr gprlgvratr ktsersqprg rrqpipkarr pegrtwaqpg ypwplygneg cgwagwllsp rgsrpswgpt dprrrsrnlg kvidtltcgf adlmgyiplv gaplggaara lahgvrvled gvnyatgnlp gcsfsiflla llscltvpa.

Spezifität: Immunoreactive with sera of HCV-infected individuals.

Produktmerkmale: Recombinant Hepatitis C Virus Nucleocapsid (core) 22 kDa

Aufreinigung: HCV-Core protein was purified by proprietary chromatographic technique.

Reinheit: > 95 % pure as determined by 10 % PAGE (coomassie staining).

Anwendungsinformationen

Applikationshinweise: HCV-Core Antigen is suitable for ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: 20mM Tris Hcl pH-8, 8M urea and 10mM beta-mercaptoethanol.

Lagerung: -20 °C

Antigendetails

Target: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Abstract: HCV C Produkte

Substanzklasse: Viral Protein

Hintergrund: The E. coli derived recombinant protein contains the HCV core nucleocapsid genotype 1b, immunodominant regions, AA 2-192, 22 kDa. The protein is fused with b-galactosidase (114 kDa) at N-terminus. Introduction: HCV is a small 50nm, enveloped, single-stranded, positive sense RNAvirus in the family Flaviviridae. HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host's immune response. Hepatitis C virus is classified into six genotypes(1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6).